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Kidney disease is emerging as an arsenic (As)-linked disease outcome, however
further evidence of this association is warranted. Our first objective for this paper
was to examine the potential renal toxicity of As exposure in Bangladesh. Our
second objective relates to examining whether the previously reported positive
association between urinary creatinine (uCrn) and As methylation may be
explained by renal function. We had hypothesized that these associations relate to
supply and demand for s-adenosylmethionine, the methyl donor for both creatine
synthesis and As methylation. Alternatively, renal function could influence both As
and creatinine excretion, or the As metabolites may influence renal function, which
in turn influences uCrn. We conducted a cross-sectional study (N5478) of adults,
composed of a sample recruited in 2001 and a sample recruited in 2003. We
assessed renal function using plasma cystatin C, and calculated the estimated
glomerular filtration rate (eGFR). Consistent with renal toxicity of As, log-uAs had a
marginal inverse association with eGFR in the 2003 sample (b525.6, p50.07),
however this association was not significant in the 2001 sample (b521.9, p50.24).
Adjustment for eGFR did not alter the associations between uCrn and the %uAs
metabolites, indicating that GFR does not explain these associations. Increased
eGFR was associated with increased odds of having %uInAs .12.2% (2001:
OR51.01, 95%CI (1.00,1.03); 2003: OR51.04, 95%CI (1.01,1.07)). In the 2003
sample only, there was a negative association between eGFR and %uDMA
(b520.08, p50.02). These results may indicate differential effects of renal function
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on excretion of InAs and DMA. Alternatively, a certain methylation pattern, involving
decreased %InAs and increased %DMA, may reduce renal function. Given that
these studies were cross-sectional, we cannot distinguish between these two
possibilities. Discrepancies between the samples may be due to the higher As
exposure, poorer nutrition, and lower As methylation capacity in the 2003 sample.
Introduction
Approximately 140 million people worldwide are chronically exposed to inorganic
arsenic (As) through contaminated drinking water, of whom approximately 57
million reside in Bangladesh [1]. In a survey of 4,997 tube wells conducted in 2000
in our study region of Araihazar, Bangladesh, 72% of wells exceeded the World
Health Organization maximum contaminant level for As of 10 mg/L, and 52%
exceeded the Bangladesh standard of 50 mg/L [2]. Exposure to inorganic As is
associated with increased risk for cancers of the skin, lung, and bladder [3] as well
as non-carcinogenic outcomes including cardiovascular disease, respiratory
illness, and neurologic deficits [4–8].
Chronic kidney disease (CKD) is emerging as another As-induced disease
outcome [9]. Elevated mortality rates from kidney diseases have been observed in
ecological studies of As-exposed populations from Utah [10], Michigan [11],
Taiwan [12], and Chile [13]. Cross-sectional studies have associated total urinary
As (uAs) with increased odds of CKD [14, 15]. Animal studies suggest that As may
cause kidney dysfunction through induction of oxidative stress in the kidney
tissue [16–18]. Our first objective for this paper was to examine the potential renal
toxicity of As exposure, measured by well water As and uAs (i.e. total uAs and uAs
metabolites), in a cross-sectional sample of Bangladeshi adults. As a marker of
renal function, we chose to measure plasma cystatin C. Very small reductions in
glomerular filtration rate (GFR) increase serum cystatin C, making it a sensitive
biomarker of GFR [19].
Our secondary objective for this paper relates to examining whether the
previously reported associations between urinary creatinine (uCrn) and As
metabolites may be explained by renal function. Arsenic metabolism, which
facilitates uAs excretion, occurs through a series of methylation and reduction
reactions which convert inorganic arsenic (InAsV+III) into monomethylarsonic
acid (MMAV), monomethylarsonous acid (MMAIII), and dimethylarsinic acids
(DMAV) [20, 21]. The methylation reactions are catalyzed by arsenic methyl-
transferase (AS3MT) [22, 23], with S-adenosylmethionine (SAM) as the methyl
donor. In urinary biomarker studies, uCrn concentration is widely used to adjust
for urine dilution when measuring an analyte in a spot urine sample [24].
However, uCrn is not indicative only of hydration status, as it is also influenced by
age, sex, race, BMI, and diet [24, 25], and in an As-exposed population in
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Bangladesh, we found that higher uCrn concentrations were associated with a
significantly lower risk for As-induced skin lesions [26].
Our group [27–32] and others [33–35] have previously reported associations
between uCrn and the percentage of total uAs that is inorganic As (%uInAs), and
the percentage that is DMA (%uDMA). These studies have consistently shown
that uCrn is positively associated with %uDMA, and negatively associated with
%uInAs, however the mechanism underlying these observations is unclear. One
explanation relates to the fact that creatine synthesis (Figure 1) consumes up to
50% of all SAM-derived methyl groups [36–38], while we estimate that
methylation of a chronic high dose of As may consume only 2–4% [39]. In
omnivores, roughly half of creatine requirements are met through dietary intake
of creatine, primarily from meat [40]. Urinary creatinine is therefore a reflection
of both dietary creatine intake and endogenous creatine synthesis [41], as well as
hydration status. Studies in rodents have demonstrated that dietary creatine
intake lowers creatine biosynthesis, thereby sparing methyl groups and lowering
homocysteine (Hcys) [42]. We hypothesize that dietary creatine intake may also
facilitate the methylation of As, and cause the observed associations between the
%uAs metabolites and uCrn.
However, because uCrn levels may also be influenced by renal function [41],
other potential explanations exist for the strong associations between the %uAs
metabolites and uCrn. One is that renal function may differentially influence the
excretion of InAs and DMA, thereby leading to a spurious association between
uCrn and the %uAs metabolites (i.e. confounding). Alternatively, As metabolites
may differentially influence renal function, which may then influence the
excretion of creatinine (i.e. mediation). Remarkably, our understanding of the
renal mechanisms of excretion of InAs is extremely limited [43–45] and, to the
best of our knowledge, no published data are currently available regarding renal
mechanisms of excretion and/or potential reabsorption of MMA or DMA.
Additionally, the effect of individual As metabolites on renal function has not
been thoroughly examined in the literature.
In summary, we had two objectives for this paper. First, we aimed to examine
the potential renal toxicity of As exposure. Second, we aimed to examine the
possibility that the associations between %uAs metabolites and uCrn may be
explained by renal function. We carried out our objectives in a cross-sectional
sample of Bangladeshi adults.
Materials and Methods
Ethics statement
This study was approved by the Institutional Review Board of the Columbia
University Medical Center and the Bangladesh Medical Research Council. All
participants gave written informed consent.
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Data availability statement
The data used for these analyses are available on request for academic, non-
commercial purposes.
Study participants
The Nutritional Influences on Arsenic Toxicity (NIAT) study [46] was a cross-
sectional study of 1,650 adults randomly selected from the larger Health Effects of
Arsenic Longitudinal Study (HEALS). HEALS is a prospective cohort study which
Figure 1. Arsenic metabolism and creatine synthesis. (A) Guanadinoacetate methyltransferase (GAMT)
and phosphatidyl ethanolamine methyltransferase (PEMT), which catalyze the synthesis of creatine (Cr) and
phosphatidylcholine, are the major consumers of S-adenosylmethionine (SAM). Arsenic methyltransferase
(AS3MT) uses quantitatively much less SAM. (B) In the first, and rate-limiting, step of Cr biosynthesis,
guanadinoacetate (GAA) is formed in the kidney by arginine:glycine amidinotransferase (AGAT). Dietary
creatine (e.g. primarily from meat) leads to pre-translational inhibition of AGAT, thereby inhibiting endogenous
creatine biosynthesis. GAA is transported to the liver, where it is methylated by GAMT to generate Cr, with
SAM as the methyl donor. SAM also serves as the methyl donor for the methylation of trivalent inorganic
arsenic (InAsIII) to monomethylarsonic acid (MMAV), and for the methylation of monomethylaronous acid
(MMAIII) to dimethylarsinic acid (DMAV). The by-product of these methylation reactions is S-
adenosylhomocysteine (SAH). Creatine, whether derived from endogenous biosynthesis or dietary sources,
is transported to tissues with high energy requirements such as skeletal muscle, heart, and brain, where it is
phosphorylated to phosphoryl-creatine (PCr). PCr is used for the regeneration of ATP during intensive
exercise. Creatine and PCr are converted non-enzymatically at a constant rate to creatinine (Crn), which is
then excreted in the urine. Image credit: Brandilyn A. Peters.
doi:10.1371/journal.pone.0113760.g001
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originally recruited approximately 12,000 adults living in Araihazar, Bangladesh.
The study region and recruitment of HEALS participants have been described
previously [47]. Araihazar was chosen because it has a wide range of As
concentrations in drinking water and is within a reasonable commuting distance
from Dhaka.
Study design
A subset of 300 people, representative of the larger cohort for total uAs, was
selected from the NIAT study for measurement of uAs metabolites [30]. An
additional random subset of 180 participants was later selected from the NIAT
study for inclusion in the current study. Cystatin C was then measured in all
N5480 participants. Participants missing data on uAs metabolites (N52) were
excluded from analysis, leaving us with a final sample size of N5478. Recruitment
for the NIAT study took place in two phases, in 2001 and in 2003, which
corresponded with the baseline survey and first follow-up survey of the larger
HEALS cohort, respectively.
Collection of biospecimens
We obtained plasma samples by venipuncture after the participants had been
sitting for 10–15 min. Blood was collected into EDTA-containing tubes and
immediately placed in IsoRack cool packs (Brinkmann Instruments, Westbury,
NY) designed to maintain samples at 0 C˚ for .6 hr. Within 4 hr, samples were
transported in hand-carried coolers containing additional ice packs to our local
laboratory situated in our field clinic in Araihazar. Samples were centrifuged at
4 C˚ and plasma separated from the cells. Plasma was then stored in aliquots at
280 C˚ and shipped frozen on dry ice to Columbia University for analysis. Spot
urine samples were collected into 50 ml acid-washed tubes, frozen at 220 C˚, and
shipped on dry ice.
Well water As
Field sample collection and laboratory analytical procedures are described
elsewhere in detail [48, 49]. Water samples were collected in 20-mL polyethylene
scintillation vials. The samples were acidified to 1% with high-purity Optima HCl
(Fisher Scientific, Pittsburg, PA, USA) at least 48 hr before analysis [50]. Water
samples were analyzed by graphite furnace atomic absorption (GFAA) with a
detection limit of 5 mg/L. Samples found to have a concentration ,5 mg/L were
reanalyzed by high-resolution inductively coupled plasma mass spectrometry after
1:10 dilution and addition of a Ge spike to correct fluctuations in instrument
sensitivity. The detection limit of the method is typically ,0.2 mg/L. A standard
with an As concentration of 51 mg/L was run multiple times in each batch. The
intra- and inter-assay coefficients of variation (CVs) for this standard were 6.01%
and 3.76%, respectively.
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Total uAs and creatinine
Total uAs was measured by GFAA spectrometry using the AAnalyst 600 graphite
furnace system (Perkin Elmer, Shelton, CT), according to the method of Nixon
et al. [51]. The intra- and inter-assay CVs for total uAs were 2.5% and 4.7%,
respectively. The laboratory participates in a quality control program run by the
Institut de Sante Publique du Quebec, Canada. Intraclass correlation coefficients
between our laboratory’s values and samples calibrated at the Quebec laboratory
were 0.99. We used a method based on the Jaffe reaction [52] to measure uCrn
concentrations. The intra- and inter-assay CVs for uCrn were 1.9% and 4.9%,
respectively.
Urinary As metabolites
Arsenic metabolites were speciated using HPLC separation of arsenobetaine
(AsB), arsenocholine (AsC), arsenate, arsenite, MMAIII+V, and DMAIII+V followed
by detection using ICP-MS [53]. The intra- and inter-assay CVs for InAsIII+V were
3.8% and 4.7%, for MMAIII+V were 4.6% and 8.9%, and for DMAIII+V were 2.0%
and 1.9%, respectively. The percentages of InAsIII+V, MMAIII+V, and DMAIII+V
were calculated using the sum of the inorganic and methylated metabolites as the
denominator.
Plasma cystatin C and eGFR
Cystatin C was measured by ELISA according to the manufacturer’s protocol
(R&D Systems Human Cystatin C Duoset Catalog# DY1196). We used a 6 point
standard curve with a high standard of 3000 pg/ml. Samples were diluted 1:2000
in PBS with 10% fetal bovine serum (Sigma Aldrich F6178). Recovery of the IFCC
certified reference material for serum cystatin C (ERM-DA 471/IFCC) ranged
from 104–114%. The intra- and inter- assay CVs were 3% and 10%, respectively.
We calculated estimated glomerular filtration rate (eGFR) using the 2012 CKD-
EPI Cystatin C equation [54].
Plasma nutrients
Plasma folate and B12 were measured by radioimmunoassay (Quantaphase II;
Bio-Rad Laboratories, Richmond, CA, USA) as previously described [46, 55]. The
intra- and inter-assay CVs for folate were 3% and 11%, respectively, and those for
B12 were 4% and 8%, respectively. Plasma total homocysteine (tHcys)
concentrations were measured by high-performance liquid chromatography
(HPLC) with fluorescence detection [56]. The intra- and inter- assay CVs for tHcy
were 5% and 8%, respectively.
Statistical analysis
Descriptive statistics were calculated for the total sample and by recruitment year,
and differences between samples were detected using the Wilcoxon rank-sum test
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for continuous variables and the Chi-square test for categorical variables. We
calculated prevalence of the 5 stages of CKD based on the National Kidney
Foundation KDOQI guidelines as follows: Stage 1 is eGFR §90 ml/min/1.73 m2
+ proteinuria, Stage 2 is eGFR 60–89 ml/min/1.73 m2 + proteinuria, Stage 3 is
eGFR 30–59 ml/min/1.73 m2, Stage 4 is eGFR 15–29 ml/min/1.73 m2, and Stage 5
is eGFR ,15 ml/min/1.73 m2. In examination of the bivariate associations
between the %uAs metabolites and eGFR, we used partial Spearman correlation
coefficients in order to eliminate the confounding effect of age and sex.
Regression models were used to examine the associations between a specific
outcome variable and set of predictors, with and without control for potential
confounding factors. Transformation was applied to variables with skewed
distributions, to meet the assumptions of linear regression for the outcome
variable, and to reduce the impact of extreme values in the predictors. Variables
that underwent natural logarithmic transformation include %uInAs, age, uAs, and
uCrn. The pattern of the associations between our predictors and outcomes of
interest were examined by using linear models for continuous outcome variables
and multinomial logistic regression analysis for categorized outcome variables.
For our first objective, to examine the potential renal toxicity of As exposure,
we used linear regression models to examine the associations of either water As
(wAs), total uAs, or speciated uAs metabolites, with the continuous outcome
eGFR. We also examined logistic regression models using CKD (eGFR ,60 ml/
min/1.73 m2) as the outcome. A priori we decided to adjust for age and sex in
these models, and uCrn in the models with total uAs or uAs metabolites as the
predictors, to adjust for urine dilution. Other potential confounders (BMI, plasma
folate, plasma B12, smoking, betel nut chewing, land ownership, education,
systolic blood pressure, and diastolic blood pressure) were considered based on
their bivariate associations with the main predictors (wAs, uAs, uAs metabolites),
and the outcome (eGFR). The control variables in the final models were those that
were associated with either of the main predictors and with the outcome (p,0.1),
and resulted in an appreciable (.10%) change in the estimated regression
coefficient for the association between a predictor and an outcome.
For our second objective, to determine whether the associations between the
%uAs metabolites and uCrn are explained by GFR, we examined the correlations
between eGFR and the %uAs metabolites, and the correlation between eGFR and
uCrn. We then applied separate regression models using uCrn to predict each
%uAs metabolite, with and without adding eGFR, and examined whether the
parameter for uCrn was attenuated upon inclusion of eGFR. A priori we decided
to adjust for age, sex, and uAs in these models. Selection of other potential
covariates was done as described above.
Analyses were performed using SAS 9.1 (SAS Institute, Cary, NC). All statistical
tests were two-sided with a significance level of 0.05.
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Results
Characteristics of the study participants for the total sample and stratified by
recruitment year are presented in Table 1. The 2001 participants were slightly
younger (p50.04), more educated (p50.09), had lower water As (p,0.0001), uAs
(p50.005), and uAs per gram uCrn (p,0.0001), lower %DMA (p50.07) and
lower eGFR (p50.02) as compared to the 2003 participants. The 2001 participants
also appeared to be better nourished, with higher plasma folate (p,0.0001) and
B12 (p50.0004) and lower plasma tHcys (p50.02). Since the 2001 sample was
different from the 2003 sample on many factors, we present separate analyses for
these groups in addition to the analyses for the total sample.
The prevalence of total CKD and individual stages of CKD by sample and
gender are presented in Table 2. The prevalence of total CKD in the total sample
was 19.87%; CKD prevalence was higher in the 2001 sample (21.20%) than in the
2003 sample (15.45%). Men in our study on average had lower eGFR, and a
higher prevalence of CKD, than women (men: eGFR 80.12 ml/min/1.73 m2, CKD
prevalence 28.10%; women: eGFR 97.62 ml/min/1.73 m2, CKD prevalence
13.43%), and this was true in both the 2001 and 2003 samples. Age, sex, smoking,
and recruitment year were all independently associated with cystatin C in this
population; these variables together accounted for 27% of the variation in cystatin
C. As expected, cystatin C was also positively associated with plasma tHcys, likely
due to the known influence of renal function on plasma tHcys concentrations
[57].
For our first objective, to assess the potential renal toxicity of As exposure, we
examined linear regression models using water As, total uAs, or speciated uAs
metabolites, to predict eGFR, adjusting for covariates (Table 3). Water As was not
significantly associated with eGFR in the total sample, 2001 sample, or 2003
sample. In the total sample, the mean difference in eGFR for a one log-unit
increase in total uAs was 22.55 ml/min/1.73 m2 (b522.55, p50.08); this effect
size was between those of the two samples (2001 sample b521.90, p50.24; 2003
sample b525.62, p50.07). Log(uInAs in mg/L) was not associated with eGFR in
the total sample, 2001 sample, or 2003 sample, while a one log-unit increase in
uMMA was significantly associated with a mean decrease in eGFR of 2.55 ml/min/
1.73 m2 (b522.55, p50.03) in the total sample. The negative association between
log(uMMA) and eGFR was observed with marginal significance in both the 2001
sample (b522.13, p50.10) and the 2003 sample (b524.48, p50.06).
Additionally, a one log-unit increase in uDMA was significantly associated with a
mean decrease in eGFR of 6.42 ml/min/1.73 m2 in the 2003 sample (b526.42,
p50.04), although this association was not significant in the total sample or 2001
sample. These results were similar without adjustment for urinary creatinine (data
not shown). In our logistic regression analysis with CKD (eGFR ,60 ml/min/
1.73 m2) as the outcome, we did not observe that total uAs, uAs metabolites, or
water As were associated with increased odds of CKD (data not shown).
For our second objective, we aimed to determine whether the associations
between uCrn and %uAs metabolites may be explained by GFR. Consistent with
Creatinine, Arsenic, and Renal Function
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previous findings, in the total sample the partial Spearman correlations
controlling for age, sex, and recruitment year indicated that uCrn was inversely
correlated with %uInAs (r520.38, p,0.0001) and %uMMA (r520.15,
p50.0009), while positively correlated with %uDMA (r50.35, p,0.0001)
(Table 4). These partial correlations were consistent between the 2001 and 2003
samples.
Plasma cystatin C had a negative partial correlation with %uInAs (r520.13,
p50.005), and this was consistent between the 2001 and 2003 samples (Table 4).
Likewise, eGFR had a positive partial correlation with %uInAs (r50.12,
p50.007). Urinary %MMA and %uDMA were not associated with plasma
cystatin C or eGFR. eGFR was not associated with uCrn in the total sample
Table 1. Characteristics of the study samples.
Total Sample (N5478) 2001 Sample (N5368) 2003 Sample (N5110)
Mean ¡ SD Range Mean ¡ SD Range Mean ¡ SD Range P-valuea
Age 36.4¡10.1 18–64 35.9¡10.1 18–64 38.1¡10.2 18–64 0.04
Male (%) 43.93 44.84 40.91 0.47
BMI (kg/m2)b 20.2¡3.2 13.9–33.3 20.2¡3.2 13.9–33.3 20.1¡3.1 14.6–28.4 0.65
Education (yrs) 3.8¡3.9 0–15 4.0¡3.9 0–14 3.3¡3.7 0–15 0.09
Current smoker (%) 28.24 28.80 26.36 0.62
Betel Nut Use (ever) (%) 32.22 30.71 37.27 0.20
Water arsenic (mg/L) 96.5¡104.3 0.1–648 86.1¡104.8 0.1–648 131.5¡95.2 0.5–504 ,0.0001
Urinary arsenic (mg/L) 130.0¡124.0 5–1026 125.0¡125.3 5–1026 146.8¡118.5 10–877 0.005
Urinary arsenic (mg/g Crn) 259.8¡235.0 13.5–2363.6 244.8¡242.4 13.5–2363.6 309.7¡201.7 37.4–1013.7 ,0.0001
Urinary creatinine (mg/dL) 63.2¡49.3 4.4–311.0 64.3¡48.8 4.4–311.0 59.3¡51.0 6.4–274.8 0.19
%DMAc 71.9¡9.0 17.8–96.5 71.5¡9.1 17.8–96.5 73.0¡8.6 41.9–87.5 0.07
%MMAc 12.9¡5.2 0.6–28.8 13.0¡5.2 0.58–28.8 12.5¡5.1 3.1–26.8 0.23
%InAsc 15.2¡7.4 0.1–79.1 15.5¡7.8 0.05–79.1 14.5¡5.5 5.2–32.0 0.25
Plasma folate (nmol/L)d 12.9¡9.5 2.9–66.2 14.1¡10.3 2.9–66.2 9.0¡4.7 2.9–28.5 ,0.0001
Plasma B12 (pmol/L) 286.6¡112.9 79.1–1171.8 295.3¡115.8 79.1–1171.8 257.3¡97.6 97.0–676.5 0.0004
Plasma tHcys (mmol/L)d, e 11.9¡7.5 2.4–72.6 11.6¡6.9 2.4–56.1 13.2¡9.1 5.8–72.6 0.02
Plasma cystatin C (ng/mL) 982.9¡317.9 438.0–4186.1 996.9¡291.9 438.0–2393.1 935.9¡390.5 471.8–4186.1 0.008
eGFR (ml/min/1.73 m2) 89.9¡25.8 12.0–154.5 88.5¡25.8 24.0–154.5 94.7¡25.5 12.0–145.4 0.02
Proteinuria (%)f 6.90 7.07 6.36 0.80
Systolic blood pressure (mm Hg)g 112.2¡15.7 60.0–183.0 111.9¡15.2 60.0–168.0 113.2¡17.3 79.0–183.0 0.76
Diastolic blood pressure (mm Hg)g 72.8¡10.7 44.0–114.0 72.8¡11.1 44.0–114.0 72.8¡9.0 54.0–98.0 0.73
History of diabetes (%)h 2.20 2.62 0.91 0.29
aChi-square and Wilcoxon’s rank-sum tests were used to test for between sample differences in categorical and continuous variables, respectively.
b2001 sample N5366, 2003 sample N5109.
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(Spearman r520.05, p50.30), 2001 sample (Spearman r520.07, p50.21), or
2003 sample (Spearman r50.01, p50.92). This result did not support the
hypothesis that GFR may serve as a confounder or a mediator of the associations
between uCrn and the %uAs metabolites. Nevertheless, we did examine regression
models using uCrn to predict each %uAs metabolite, adjusting for total uAs, age,
sex, smoking, and recruitment year, with and without adjustment for eGFR
(Table 5).
We used multinomial logistic regression models to examine the pattern of
association of uCrn and eGFR with the %uAs metabolites. A multinomial logistic
model in the 2001 sample categorizing %uInAs at tertiles revealed a threshold
effect of eGFR on %uInAs, in which eGFR was associated with increased odds of
having %uInAs above the first tertile, while this positive association could not be
observed with linear regression. Since the effect for the upper tertile vs. lower
tertile was similar to that for the middle tertile vs. lower tertile, we dichotomized
%uInAs at the lower tertile (at 12.2%, derived from the 2001 sample) to create a
binary outcome for logistic regression. Linear regression models were applied to
the continuous outcomes of %uMMA and %uDMA. Adding eGFR into the
models did not appreciably change the estimated parameter of uCrn in any of the
Table 2. Prevalence of chronic kidney disease (CKD) stages by gender.





















89.93 80.12 97.62 88.51 78.90 96.31 94.70 84.58 101.71
Total CKD (%) 19.87 28.10 13.43 21.20 29.09 14.78 15.45 24.44 9.23
Stage 1 (%) 2.51 0.95 3.73 1.90 0 3.45 4.55 4.44 4.62
Stage 2 (%) 3.14 3.81 2.61 3.80 4.24 3.45 0.91 2.22 0
Stage 3 (%) 13.60 21.90 7.09 14.95 23.64 7.88 9.09 15.56 4.62
Stage 4 (%) 0.42 0.95 0 0.54 1.21 0 0 0 0
Stage 5 (%) 0.21 0.48 0 0 0 0 0.91 2.22 0
doi:10.1371/journal.pone.0113760.t002
Table 3. Linear regression models using log(total urinary As in mg/L), log(uAs metabolites in mg/L), or log(water As in mg/L) to predict eGFR.
















Log(Urinary As)a 22.55 (1.44) 0.08 29.51 21.90 (1.62) 0.24 26.57 25.62 (3.04) 0.07 41.95
Log(uInAs)a 20.66 (0.98) 0.50 29.11 20.77 (1.07) 0.47 26.40 0.21 (2.52) 0.93 40.05
Log(uMMA)a 22.55 (1.14) 0.03 29.79 22.13 (1.30) 0.10 26.83 24.48 (2.35) 0.06 42.08
Log(uDMA)a 22.24 (1.40) 0.11 29.42 21.39 (1.58) 0.38 26.45 26.42 (3.03) 0.04 42.54
Log(Water As)b 20.67 (0.56) 0.23 29.22 20.59 (0.60) 0.32 26.44 21.44 (1.77) 0.42 40.35
aAdjusted for log(age), sex, current smoking, log(urinary creatinine), and recruitment year (total sample only).
bAdjusted for log(age), sex, current smoking, and recruitment year (total sample only).
doi:10.1371/journal.pone.0113760.t003
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models. Results were similar when including water As as a covariate in these
models in place of total uAs (data not shown).
As mentioned above, eGFR was positively associated with %uInAs in partial
Spearman correlations within both samples (Table 4); upon covariate adjustment
in regression models, these positive associations remained significant (Table 5).
An increase in eGFR was associated with increased odds of having %uInAs above
12.2% (OR51.02, 95% CI (1.01, 1.03)). In the 2003 sample, the positive
association between eGFR and log(%uInAs) was linear and significant when
modeled with linear regression; a one unit increase in eGFR was associated with a
0.7% increase in %uInAs (b50.007, p,0.0001; data not shown). eGFR was not
associated with %uMMA (b520.01, p50.43), and this was consistent in both the
2001 and 2003 samples. Finally, in the 2003 sample, a one unit increase in eGFR
was associated with a mean decrease in %uDMA of 0.08 (b520.08, p50.02) in
the covariate-adjusted model, however this association was not observed in the
total sample or the 2001 sample.
Discussion
For our first objective, we aimed to explore the potential renal toxicity of As.
While water As was not associated with eGFR, we observed a marginally
significant negative association between total uAs and eGFR in the total sample;
this association remained marginally significant in the 2003 sample, while the
association was negative but not significant in the 2001 sample. Additionally, the
concentration of uMMA was a significant negative predictor of eGFR in the total
sample, while uDMA was a negative predictor of eGFR in the 2003 sample only.
The negative association between total uAs and eGFR in the 2003 sample might be
Table 4. Partial Spearman correlation coefficients for associations between % urinary As metabolites and urinary creatinine, cystatin C, and eGFR, adjusting
for sex and age (and recruitment year in the total sample only).
%InAs %MMA %DMA
Total Sample (N5478)
Urinary creatinine (mg/dL) 20.38 (,0.0001)a 20.15 (0.0009) 0.35 (,0.0001)
Plasma cystatin C (ng/ml) 20.13 (0.005) 0.04 (0.43) 0.05 (0.28)
eGFR (ml/min/1.73 m2) 0.12 (0.007) 20.03 (0.50) 20.05 (0.29)
2001 Sample (N5368)
Urinary creatinine (mg/dL) 20.34 (,0.0001) 20.13 (0.02) 0.32 (,0.0001)
Plasma cystatin C (ng/ml) 20.10 (0.05) 0.03 (0.53) 0.04 (0.47)
eGFR (ml/min/1.73 m2) 0.10 (0.06) 20.03 (0.62) 20.04 (0.45)
2003 Sample (N5110)
Urinary creatinine (mg/dL) 20.51 (,0.0001) 20.24 (0.01) 0.43 (,0.0001)
Plasma cystatin C (ng/ml) 20.21 (0.03) 0.03 (0.75) 0.09 (0.33)
eGFR (ml/min/1.73 m2) 0.20 (0.04) 20.04 (0.68) 20.08 (0.43)
ar (p-value), all such values.
doi:10.1371/journal.pone.0113760.t004
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attributed to the concentration of uMMA and uDMA, while in the 2001 sample
the negative association may have been attributed to the concentration of uMMA.
The 2003 sample had significantly higher total uAs concentrations, and uAs
metabolite concentrations, relative to the 2001 sample, which may explain the
stronger associations in the 2003 sample. Since the majority of total uAs consists
of DMA, it is not surprising that the negative association between total uAs and
eGFR in the 2003 sample would be attributed to uDMA. On the other hand, the
negative association between uMMA concentration and eGFR may be due to the
particularly high toxicity of MMA, as has been demonstrated in in vitro [58] and
human studies [59].
Our finding of a negative association between total uAs and eGFR is consistent
with other studies showing a negative association between total uAs and eGFR
[9, 14, 15] or a positive association between total uAs and serum cystatin C [60]. A
prospective study among children in Bangladesh observed a marginal negative
association between total uAs at infancy and eGFR at 4.5 years old [61]. Total uAs
Table 5. Logistic and linear regression models using uCrn and eGFR to predict %uAs metabolites.
Total Sample (N5478) 2001 Sample (N5368) 2003 Sample (N5110)
Logistic models
Outcome Modela Predictor OR (95%
CI)
P R2 (%)b OR (95%
CI)








,0.0001 20.45 0.26 (0.17,
0.41)







,0.0001 22.27 0.26 (0.16,
0.40)











Outcome Modela Predictor B (SE) P R2 (%) B (SE) P R2 (%) B (SE) P R2
(%)

























%uDMA Model 1 Log (Urinary
Creatinine)
5.72 (0.57) ,0.0001 20.52 5.34 (0.67) ,0.0001 17.87 7.05 (1.15) ,0.0001 30.73
Model 2 Log(Urinary
Creatinine)








aWe examined confounding or mediation of associations between uCrn and %As metabolites by using nested models, with and without control for eGFR;
Model 1 parameters are log(age), sex, current smoking, log(total uAs), log(uCrn), and recruitment year (in total sample only); Model 2 parameters are
log(age), sex, current smoking, log(total uAs), log(uCrn), eGFR, and recruitment year (in total sample only).
bGeneralized R2.
cProbability modeled is %uInAs .12.2 (total sample: %uInAs #12.2 N5168, %uInAs .12.2 N5310; 2001 sample: %uInAs #12.2 N5123, %uInAs .12.2
N5245; 2003 sample: %uInAs #12.2 N545, %uInAs .12.2 N565).
doi:10.1371/journal.pone.0113760.t005
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has also been associated with increased urinary albumin [62, 63] and protein [64],
and markers of renal tubular damage including increased urinary b2 micro-
globulin [15, 62, 65] and urinary N-acetyl-b-D-glucosaminidase (NAG) [62, 66].
Arsenic exposure has been associated with elevated mortality rates from kidney
diseases in several populations [10–13]. Given the negative direction of
association between uAs and eGFR, it is unlikely that this finding can be explained
by the influence of GFR on the excretion of As in urine. Our finding is suggestive
of the renal toxicity of As exposure, as measured by urinary As.
Although few studies have evaluated the prevalence of kidney diseases in
Bangladesh, the CKD prevalence in our population in Araihazar was high in
comparison with another Bangladeshi population located in Mirpur, Dhaka [67].
Huda et al. (2012) estimated GFR from serum creatinine using the Modification
of Diet in Renal Disease (MDRD) equation in N51,000 adults in Mirpur, and
found an average CKD prevalence of 13.1%. There may be several explanations for
the higher CKD prevalence in our study. The first is that we used an ELISA
method to measure cystatin C, which could potentially result in some
misclassification given certain limitations in the precision of the technique.
However, we do not believe that this alone could account for the large difference.
The second explanation is that GFR estimating equations have not been
extensively validated in South Asian populations, and may over- or under-
estimate the true prevalence of CKD. A study in Pakistan found that the MDRD
equation overestimated GFR as compared with a creatinine clearance test [68],
which may explain why the Mirpur study had higher eGFR on average. The CKD-
EPI equation that we have utilized has not yet been validated in a South Asian
population. The reason for the difference in eGFR between the 2001 and 2003
samples remains unclear.
We also compared the average cystatin C in the 2001 and 2003 samples with age
and sex stratified cystatin C averages from the third United States National Health
and Nutrition Examination Survey (NHANES) [69]. Across all age and sex
categories outlined in the NHANES study for which we had sufficient sample size
(N.5), average cystatin C in both the 2001 and 2003 samples was higher than in
NHANES, with the exception of 20–39 year old women in the 2003 sample who
had similar cystatin C to the respective NHANES women. Consistent with the
NHANES data, in our population cystatin C was higher in males than in females
in every age category.
For our second objective, we aimed to determine whether GFR may explain the
strong and consistent positive associations between uCrn and uAs methylation in
this and previous studies [27–35]. We considered that GFR may explain these
associations in one of two ways: one, that GFR may differentially influence the
excretion of the As metabolites, and also influence creatinine excretion (i.e.
confound the association), or two, that the As metabolites may differentially
influence GFR, which would then influence creatinine excretion (i.e. mediate the
association). Given our cross-sectional analysis, we are not able to distinguish
between a confounding or meditational effect. However, adjustment for eGFR did
not attenuate these associations, indicating that glomerular filtration does not
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explain the strong associations between uCrn and the %uAs metabolites (i.e. it is
neither a confounder nor a mediator). eGFR was not associated with uCrn; this is
not surprising, given that uCrn concentration is not a sensitive marker of renal
function. Serum creatinine itself is not sensitive to moderate reductions in GFR
[70]. Although creatinine is freely filtered at the glomerulus at a constant rate, it is
secreted by the proximal tubular cells into the urinary space at a non-constant
rate. When GFR decreases, tubular secretion of creatinine increases to offset the
rise in serum creatinine [70]. This non-constant tubular secretion of creatinine, in
addition to the strong dependence of uCrn on hydration status, is likely the reason
we observed no association between eGFR and uCrn.
The strong associations between uCrn and %uAs metabolites may instead be
due to the shared metabolic pathway of methylated As metabolites and creatine, as
creatine biosynthesis is produced via the methylation of guanadinoacetate [71], a
process that consumes a considerable amount of SAM [38]. Alternatively, it is
possible that uCrn and the uAs metabolites are related due to similar renal
handling in the proximal tubule. In humans, uCrn secretion is mediated by the
organic cation transporter OCT2 at the basolateral membrane, and by P-
glycoprotein 1 (P-gp, also known as multidrug resistance protein 1 (MDR1) or
ATP-binding cassette sub-family B member 1 (ABCB1)) at the apical membrane
[72–74], however little is known regarding the transporters mediating As
secretion, and whether these transporters may have differential affinity for the
different As species. There is evidence that cellular efflux of arsenite may be
mediated by P-gp. Rat liver epithelial cells with acquired As tolerance have
reduced As accumulation and increased expression of P-gp, while P-gp inhibition
abolishes this tolerance [75]. Additionally, P-gp knockout mice are more sensitive
to As-induced lethality and tissue damage, and accumulate more As in tissues
(including kidney) following arsenite administration, than wild type mice [76].
The mutual utilization of P-gp by As and creatinine provides a potential link
between As and creatinine secretion. Finally, creatinine may be associated with the
urinary As metabolite profile circumstantially: experiments in dogs have revealed
that arsenate reabsorption in the proximal tubule is sensitive to urine flow, with
increased urine flow depressing arsenate reabsorption [44]. Since increased urine
flow would result in enhanced arsenate excretion, and decreased uCrn (more
diluted urine), this could result in a negative association between %uInAs and
uCrn. Further research in this area is warranted to determine which transporters
are responsible for As reabsorption and secretion within the proximal tubule,
whether As may interfere with creatinine secretion or vice versa, and whether
urine flow may be an important modifier of As reabsorption in humans. A
limitation of this study is that we have not measured biomarkers of proximal
tubular damage, so we are unable to examine the effects of As exposure and As
methylation capacity on the proximal tubule, and the influence this may have on
uCrn.
Interestingly, in both the 2001 and 2003 samples we found that eGFR was
positively associated with %uInAs, independently of uCrn. Additionally, we
observed that eGFR was negatively associated with %uDMA in the 2003 sample
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only. Given that this was a cross-sectional study, there are two potential
explanations for these findings aside from unmeasured confounding: (a) GFR
differentially influences the renal excretion of the As metabolites, and (b) the As
metabolites are differentially detrimental to kidney function. We discuss both
possibilities below.
Possibility (a): GFR differentially influences the renal excretion of
As metabolites
From the experiments of Ginsburg (1963) on the renal handling of arsenate in
dogs, we know that arsenate is reabsorbed in the proximal tubule, and that
increased urine flow depresses arsenate reabsorption, i.e. enhances its excretion
[44]. In adult cancer patients with varying degrees of renal impairment
undergoing arsenic trioxide treatment, mild to severe renal impairment decreased
the renal clearance of InAs, and reduced both total As excretion and the
percentage of the As dose excreted as arsenite [77]. These data indicate that
improved GFR may result in improved excretion of InAs, which could be the
reason that we observe a positive association between %uInAs and eGFR. This
reason may also explain why we observe a negative association between %uDMA
and eGFR in the 2003 sample, since the sum of %uInAs, %uMMA, and %uDMA
within each individual is equal to 100%. Unfortunately, little is known regarding
the renal handling and excretion mechanisms of MMA and DMA, so it is unclear
whether the association between %uDMA with eGFR could be attributed to this
alternative explanation. In the adult cancer patients from the above-mentioned
study, mild to severe renal impairment resulted in increased serum concentrations
of MMA and DMA, suggesting reduced renal clearance of these metabolites,
although this data was not explicitly provided [77].
Possibility (b): the As metabolites are differentially detrimental to
kidney function
It is unlikely that high InAs exposure would result in improved GFR. InAs
exposure results in mitochondrial toxicity in rat and human kidney proximal
tubule cells [78, 79]. Mice exposed to arsenite had increased urinary N-acetyl-b-
D-glucosaminidase (NAG; a marker of tubular damage) and tubular atrophy in
the renal medulla [80]. Exposure of dogs to arsenate resulted in degeneration of
the renal tubular epithelium at the lowest dose used (0.73 mg/kg), while
reductions in creatinine clearance were only observed at higher doses [81]. An
important caveat of these in vivo experiments is that the doses used are very high
and much shorter in duration relative to the As intake from drinking water by
humans in Bangladesh and other parts of the world. Therefore it is yet unclear
what effect prolonged low dose InAs exposure would have on indices renal
function.
While we do not propose that the positive association observed in our study
between %uInAs and eGFR is indicative of a beneficial effect, it may be that a
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certain As methylation profile is detrimental to renal function. Since the sum of
%uInAs, %uMMA, and %uDMA within each individual is equal to 100%, if one
percent metabolite increases, another decreases. We therefore cannot know what
metabolite(s) may be driving the associations that we observe with eGFR. In
human studies, increased %uMMA has been associated with increased odds for a
variety of diseases, including atherosclerosis, bladder cancer, lung cancer, skin
cancer, and skin lesions [59, 82]. We did not observe that %uMMA was associated
with eGFR in this study, although the concentration of MMA in urine was
associated with decreased eGFR. In the 2001 sample, a methylation pattern of
decreased %uInAs is associated with reduced eGFR, and in the 2003 sample, a
methylation pattern of decreased %uInAs and increased %uDMA is associated
with reduced eGFR. Very few studies have examined the associations of As
metabolites with renal function, and therefore little is known regarding the
expected direction of these associations. One study in Taiwan found that urinary
%MMA was associated with lower eGFR, while urinary %DMA was associated
with greater eGFR, however these associations were fully attenuated in covariate-
adjusted models [14]. A cross-sectional study in American Indians in the U.S.
found the prevalence of albuminuria (indicating glomerular and/or tubular
damage) to be significantly reduced in the 2nd–4th quartiles of %uMMA, as
compared with the lowest quartile, in an adjusted model [63].
While methylation of InAs to DMA is considered a detoxification mechanism
[32], in that it is crucial for As elimination from the body [83], As methylation
results in intermediate metabolites, such as MMAIII and possibly DMAIII, which
are more toxic than InAsIII and their pentavalent counterparts, MMAV and DMAV
[58]. DMA has a short circulating half-life and is the most prevalent As metabolite
found in urine [84], so it is possible that the kidney tubules are exposed to DMA
to a greater extent than other tissues, and that this higher dosimetry may be
detrimental to kidney function. Since we only see an association between eGFR
and %uDMA in the 2003 sample, this finding requires confirmation in future
studies. Differences in As exposure, nutrition, and methylation capacity between
the 2001 and 2003 samples may have accounted for the discrepancy.
Strengths of this study include the measurement of a sensitive biomarker of
GFR, cystatin C, the speciation of As metabolites, and the large sample size. An
important limitation of this study was that we did not measure markers of tubular
damage, and were therefore unable to determine the effects of As exposure and/or
methylation capacity on the renal tubules. The results from this study indicate
areas for future research. Although our results suggest that the associations
between %uAs metabolites and uCrn are not explained by glomerular filtration, it
is also possible that the As metabolites and creatinine may share a mechanism of
renal secretion that has not yet been explored. Additionally, due to the cross-
sectional nature of this study, we cannot discern whether renal function may
differentially influence the excretion of As metabolites, rather than the As
methylation profile influencing renal function. Our results suggest that total As
exposure may be detrimental to renal function; however, discrepant findings
between our two study samples indicate a need for confirmation of this in future
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studies. Prospective studies examining the association between As exposure, As
methylation capacity, and CKD incidence are warranted.
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